Natalie J. Dorà
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Natalie J. Dorà has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- David J. Price
The University of Edinburgh
1 shared publication - Dirk Jan Kleinjan
University of Edinburgh
1 shared publication - John D. West
Genes and Development Group, Centre for Integrative Physiology, Clinical Sciences, University of Edinburgh Medical School, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK
1 shared publication - Jon Martin Collinson
University of Aberdeen, School of Medicine, Medical Sciences and Nutrition
1 shared publication - Martine Manuel
Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, UK
1 shared publication - Robert E. Hill
Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh
1 shared publication
Latest Publications
- Open Access
- 5 October 2018
- Published by Springer Nature in BMC Research Notes
- Vol. 11 (1) , 705
A conditional Pax6 depletion study with no morphological effect on the adult mouse corneal epithelium
The corneas of heterozygous Pax6+/− mice develop abnormally and deteriorate further after birth but it is not known whether the postnatal deterioration is predetermined by abnormal development. Our objective was to identify whether depletion of Pax6 in adult mice caused any corneal abnormalities, similar to those in Pax6+/− mice, where Pax6 levels are low throughout development and adulthood. We used two tamoxifen-inducible, Cre-loxP experimental strategies to deplete Pax6 either ubiquitously or in a restricted range of cell types. In a preliminary study, ubiquitous depletion of Pax6 by tamoxifen treatment of E9.5 CAG-CreERTg/−;Pax6fl/fl embryos affected eye development. Tamoxifen treatment of 12-week old, adult CAG-CreERTg/−;Pax6fl/+ and CAG-CreERTg/−;Pax6fl/fl mice resulted in weak and/or patchy Pax6 immunostaining in the corneal epithelium but caused no corneal abnormalities. GFP staining in tamoxifen-treated CAG-CreERTg/−;RCE:loxP reporter mice was also patchy. We attribute patchy Pax6 staining to mosaic deletion of the Pax6fl allele, probably caused by mosaic CAG-CreERTg expression. In a parallel study, we treated adult Krt19-CreERTg/−;Pax6fl/+ mice with tamoxifen to try to deplete Pax6 in limbal epithelial stem cells (LESCs) which replenish the corneal epithelium. However, Pax6 staining remained strong after a 12-week chase period so the Krt19-CreERTg/− transgene may have failed to target LESCs.
- 5 October 2018
- Published by Springer Nature in BMC Research Notes
- Vol. 11 (1) , 705
Open AccessA conditional Pax6 depletion study with no morphological effect on the adult mouse corneal epithelium
The corneas of heterozygous Pax6+/− mice develop abnormally and deteriorate further after birth but it is not known whether the postnatal deterioration is predetermined by abnormal development. Our objective was to identify whether depletion of Pax6 in adult mice caused any corneal abnormalities, similar to those in Pax6+/− mice, where Pax6 levels are low throughout development and adulthood. We used two tamoxifen-inducible, Cre-loxP experimental strategies to deplete Pax6 either ubiquitously or in a restricted range of cell types. In a preliminary study, ubiquitous depletion of Pax6 by tamoxifen treatment of E9.5 CAG-CreERTg/−;Pax6fl/fl embryos affected eye development. Tamoxifen treatment of 12-week old, adult CAG-CreERTg/−;Pax6fl/+ and CAG-CreERTg/−;Pax6fl/fl mice resulted in weak and/or patchy Pax6 immunostaining in the corneal epithelium but caused no corneal abnormalities. GFP staining in tamoxifen-treated CAG-CreERTg/−;RCE:loxP reporter mice was also patchy. We attribute patchy Pax6 staining to mosaic deletion of the Pax6fl allele, probably caused by mosaic CAG-CreERTg expression. In a parallel study, we treated adult Krt19-CreERTg/−;Pax6fl/+ mice with tamoxifen to try to deplete Pax6 in limbal epithelial stem cells (LESCs) which replenish the corneal epithelium. However, Pax6 staining remained strong after a 12-week chase period so the Krt19-CreERTg/− transgene may have failed to target LESCs.